Exploration of the hepatoprotective effect and mechanism of magnesium isoglycyrrhizinate in mice with arsenic trioxide-induced acute liver injury

MIAOMIAO LIU1, BIN ZHENG1, PANPAN LIU1, JIANPING ZHANG2, XI CHU3, CHUNHUI DONG3, JING SHI3, YINGRAN LIANG1, LI CHU1, YANSHUANG LIU4 and XUE HAN1,5

1Department of Pharmacology, School of Pharmacy; 2Department of Pharmacology, School of Basic Medicine, Hebei University of Chinese Medicine, Shijiazhuang, Hebei 050200; 3Department of Pharmacy, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei 050011; 4Hebei Key Laboratory of Integrative Medicine on Liver-Kidney Patterns, Institute of Integrative Medicine, College of Integrative Medicine, Hebei University of Chinese Medicine, Shijiazhuang, Hebei 050200; 5Hebei Higher Education Institute Applied Technology Research Center on TCM Formula Preparation, Shijiazhuang, Hebei 050091, P.R. China

Received December 15, 2020; Accepted March 15, 2021

DOI: 10.3892/mmr.2021.12077

Correspondence to: Professor Yanshuang Liu, Hebei Key Laboratory of Integrative Medicine on Liver-Kidney Patterns, Institute of Integrative Medicine, College of Integrative Medicine, Hebei University of Chinese Medicine, 3 Xingyuan Road, Shijiazhuang, Hebei 050200, P.R. China
E-mail: 957708622@qq.com

Professor Xue Han, Department of Pharmacology, School of Pharmacy, Hebei University of Chinese Medicine, 3 Xingyuan Road, Shijiazhuang, Hebei 050200, P.R. China
E-mail: hanxuecc@126.com

Key words: magnesium isoglycyrrhizinate, arsenic trioxide, inflammatory, apoptosis, oxidative stress, Kelch-like ECH-associated protein 1/nuclear factor erythroid 2-related factor 2 signaling pathway

Abstract. Arsenic trioxide (ATO)-induced hepatotoxicity limits the therapeutic effect of acute myelogenous leukemia treatment. Magnesium isoglycyrrhizinate (MgIG) is a natural compound extracted from licorice and a hepatoprotective drug used in liver injury. It exhibits anti-oxidant, anti-inflammatory and anti-apoptotic properties. The aim of the present study was to identify the protective action and underlying mechanism of MgIG against ATO-induced hepatotoxicity. A total of 50 mice were randomly divided into five groups (n=10/group): Control; ATO; MgIG and high- and low-dose MgIG + ATO. Following continuous administration of ATO for 7 days, the relative weight of the liver, liver enzyme, histological data, antioxidant enzymes, pro-inflammatory cytokines, cell apoptosis and changes in Kelch-like ECH-associated protein 1/nuclear factor erythroid 2-related factor 2 (Keap1-Nrf2) signaling pathway were observed. MgIG decreased liver injury, decreased the liver weight and liver index, inhibited oxidative stress and decreased the activity of glutathione, superoxide dismutase and catalase, production of reactive oxygen species and levels of pro-inflammatory cytokines, including IL-1β, IL-6 and TNF-α. Western blotting showed a decrease in Bax and caspase-3. There was decreased cleaved caspase-3 expression and increased Bcl-2 expression. MgIG notably activated ATO-mediated expression of Keap1 and Nrf2 in liver tissue. MgIG administration was an effective treatment to protect the liver from ATO-induced toxicity. MgIG maintained the level of Nrf2 in the liver and protected the antioxidative defense system to attenuate oxidative stress and prevent ATO-induced liver injury.

Introduction

Arsenic is a common constituent of the Earth's crust and has been used in traditional Chinese medicine to treat a number of diseases, such as leukemia, psoriasis, syphilis and tuberculosis (1,2). Arsenic trioxide (ATO) has been the cornerstone of the treatment of acute promyelocytic leukemia (APL) and other types of hematopoietic malignancy since its first application in the 1970s at Harbin Medical University; its efficacy has been proved in clinical trials (3). The United States Food and Drug Administration approved ATO for the treatment of APL in September 2000 (4). High-dose ATO is used as an effective chemotherapy drug in the treatment of certain types of cancers; however, toxic side effects are of concern (5). ATO has been shown to be the most effective single agent for the treatment of APL, and following the co-treatment of ATO and all-trans retinoic acid, long-term survival of patients with APL has been improved to 80-90% (6-8). An increasing number of studies have consistently shown that ATO is effective against other cancer types, including hepatocellular carcinoma, pancreatic cancer and lung cancer (9,10). In past decades, clinical data have shown that excessive use of ATO causes hepatotoxicity, nephrotoxicity and cardiotoxicity (11-15).
The liver removes toxins and drugs, but it can also be destroyed by these harmful substances (11,16). Arsenic induces hepatotoxicity by oxidative stress (17,18). ATO generates reactive oxygen species (ROS), including hydroxyl radicals and superoxide anions, which decrease equilibrium and disturb natural oxidation via complex redox reactions with endogenous oxidants (19). Oxidative stress occurs when pro-oxidants overpower anti-oxidants in the living organisms (20). Pro-oxidants are chemicals that can either generate ROS or compromise anti-oxidants in cells (21). A high concentration of redox signaling of ROS is commonly observed with cell damage and metabolic dysregulation, including lipid peroxidation, and permanent protein and DNA degeneration (22). Thus, the liver is the primary organ susceptible to pathological cascades of oxidative stress (23). Parenchymal cells are most vulnerable in an oxidative environment (24). In order to control the generation of ROS in the liver, both enzymatic and non-enzymatic systems are involved in maintaining redox homeostasis (25). The imbalance between ROS production and the antioxidant system is maintained by key enzymes, such as catalase (CAT), superoxide dismutase (SOD) and glutathione (GSH) (26,27). Malondialdehyde (MDA) is an end product of lipid peroxidation and is used as an indicator of oxidative damage in vivo (28). In addition to the significant role of oxidative stress, many reports suggest that the activity of inflammatory cytokines and apoptotic proteins increases with the etiology of hepatotoxicity (29,30).

High levels of ROS act as mediators of inflammation and induce peripheral inflammation, but other studies have shown that ATO alters expression levels of pro-inflammatory cytokines, such as TNF-α, IL-1β and IL-6 (31,32). When antioxidant responses are overwhelmed, ROS damage to cells leads to necrosis or apoptosis, which is manifested by oxidative stress and inflammation (33). Apoptosis is characterized by well-defined features, including cellular morphological changes, activation of caspase-3 and cleaved caspase-3 and imbalance of Bax/Bcl-2 (34-36).

Nuclear factor erythroid 2-related factor 2 (Nrf2) is a sensitive sensor that is key to cellular defense against oxidative species and toxic damage; it inhibits oxidative stress by upregulating Nrf2-driven antioxidants (37). Previous research has shown that adropin protects against liver injury in nonalcoholic steatohepatitis via Nrf2-mediated antioxidant capacity (38). Under normal conditions, cells maintain low constitutive levels of Nrf2-target genes via the Kelch-like ECH-associated protein 1 (Keap1)-dependent E3 ubiquitin ligase complex, which directly leads to continual ubiquitination and subsequent degradation of the transcription factor Nrf2 in the cell cytoplasm (39,40). Under oxidative stress, Keap1 is inactivated, leading to the release of Nrf2 from Keap1. The switching on and off of Nrf2 protects cells from free radical damage and promotes cell survival (41). Therefore, antioxidants may serve key roles in preventing ATO-induced hepatotoxicity.

Magnesium isoglycyrrhizinate (MgIG; Fig. 1) is a magnesium salt of the 18-α glycyrrhizic acid stereoisomer. It is a novel molecular compound extracted from licorice root (42). In China and Japan, it is used as a hepatoprotective agent and inhibits inflammation, improves liver function and stabilizes cell membranes (43). MgIG has been used as a hepatoprotective and anti-inflammatory agent in the clinical treatment of inflammatory liver disease due to its effective role in hepatitis response and liver function recovery (44). According to our previous research, MgIG ameliorates doxorubicin-induced cardiotoxicity and hepatotoxicity via anti-oxidant and anti-apoptotic mechanisms (42,45). To the best of our knowledge, however, the potential effect and mechanism of MgIG on hepatotoxicity caused by ATO has not yet been reported.

The present study aimed to evaluate the protective effect and potential mechanism of MgIG on ATO-induced hepatotoxicity, including oxidative stress, inflammatory responses, apoptosis and activation of the Keap1-Nrf2 signaling pathway.

Materials and methods

Chemicals and reagents. MgIG (purity, 99.3%) was purchased from Chia Tai Tianqing Pharmaceutical Group Co., Ltd. ATO parenteral solution was purchased from Beijing SL Pharmaceutical Co., Ltd. All other chemicals were purchased from Sigma-Aldrich (Merck KGaA) unless otherwise specified.

Animals and treatment. A total of 50 adult male KunMing mice (age, 6-7 weeks; weight, 18-22 g) were provided by Experimental Animal Center (Hebei Medical University, Shijiazhuang, China). All mice were housed in plastic cages (n=10/cage) under standard conditions (20-24°C) and 55±5% relative humidity with a 12-h dark-light cycle environment and ad libitum access to pellet food and water. All animal experiments were approved by the Ethics Committee for Animal Experiments of Hebei University of Chinese Medicine (approval no. DWLL2020005; approval date, 9 January, 2020).

Animals were randomly divided into the following groups (n=10/group): Control [CON, normal saline, intraperitoneal (i.p.) injection, 0.1 ml/kg/day]; ATO (i.p., 5 mg/kg/day); MgIG-alone (MgIG, i.p., 50 mg/kg/day); high-MgIG + ATO (H-MgIG, i.p., 50 mg/kg/day MgIG + 5 mg/kg ATO); and low-MgIG + ATO (L-MgIG, i.p., 25 mg/kg/day MgIG + 5 mg/kg ATO). The hepatotoxicity model was established via i.p. injection with ATO (5 mg/kg). The CON group received isovolumic normal saline, as previously described (46). The L-MgIG and H-MgIG groups were given 25 and 50 mg/kg MgIG, respectively, followed by 5 mg/kg ATO 6 h later. Dose selection of ATO and MgIG was determined according to previous literature (47,48). The mice were sacrificed after 7 days of continuous treatment. After 7 days, sodium pentobarbital (50 mg/kg) was used to anesthetize mice and mice were weighed on an electronic balance to the nearest milligram. Then, blood (0.5-1.2 ml) was collected by exsanguination from the abdominal aorta for biochemical analysis. Euthanasia of mice was performed by overdose with i.p. injection of sodium pentobarbital (200 mg/kg) and was confirmed by absence of respiration and heartbeat. Liver was collected for further analysis (49).

Blood collection and serum preparation. The weight was recorded for each mouse, followed by i.p. injection by sodium pentobarbital (50 mg/kg). The blood sample was collected and centrifuged at 1,500 x g for 10 min at room temperature.
The serum was aspirated into clean, dry tubes and then frozen at -20˚C for analysis.

Liver tissue collection and homogenate preparation. Liver was removed after sacrificing the mice. The livers were weighed on an electronic balance to the nearest milligram and the relative weight of the liver was calculated using the following formula: Index weight=organ weight/body weight x100%. The livers were then washed with ice-cold saline and homogenized at 12,000 x g at 4˚C for 10 min in PBS (pH 7.4; w/v; 1 g tissue with 9 ml PBS). The supernatant was stored at -20˚C and different parameters were assayed.

Evaluation of histopathology. Livers were excised and small pieces were carefully removed from experimental animals. The tissue was dissected and fixed with ice-cold 4% paraformaldehyde overnight at 4˚C, embedded in paraffin, cut into 4 µm-thick slices and stained with 0.1% hematoxylin for 15 min and 0.5% eosin for 5 min, both at room temperature, according to standard procedures. Pathohistological changes were observed by light microscopy (magnification, x400).

Measurement of levels of ROS. Dihydroethidium was used to monitor cellular production of ROS. Fresh liver tissue was embedded and sliced, as aforementioned. Liver tissue was incubated at 37˚C in the dark for 1 h. A fluorescence microscope was used to measure the nucleus of liver following staining with 5 mg/ml DAPI for 20 min at room temperature with an excitation source of 510-560 nm and an emission wavelength of 590 nm. ROS generation was visualized and analyzed using a high-content screening system (Leica DM4000B; Leica Microsystems GmbH). ROS production was quantified using Image-Pro Plus 6.0 software (Media Cybernetics, Inc.). All experiments were repeated at least three times.

Detection of biochemical indices in serum. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) are significant predictors of liver injury (50). The serum activity of ALT (cat. no. C010-3-1), AST (cat. no. C009-3-1), SOD (cat. no. C001-3-2) and CAT (cat. no. C007-1-1), GSH (cat. no. C006-2-1), as well as the level of MDA (cat. no. C003-1-2) were detected by commercial kits according to the manufacturer's instructions (all Nanjing Jiancheng Bioengineering Institute).

Quantification of levels of IL-1β, IL-6 and TNF-α. The levels of IL-1β (cat. no. 88-7013-88), IL-6 (cat. no. 88-7064-88) and TNF-α (cat. no. 88-7324-88) were measured and calculated using ELISA kits, according to the manufacturers' instructions (all Thermo Fisher Scientific, Inc.).

Reverse transcription-quantitative (RT-q)PCR. Total RNA was extracted from liver using TRizol® reagent (cat. no. G3013; Wuhan Servicebio Technology Co., Ltd.). RT was performed using a TIANScript RT kit (cat. no. G3330-100; Wuhan

Figure 1. Chemical structure of magnesium isoglycyrrhizinate.
Servicebio Technology Co., Ltd.) according to the manufacturer's instructions. The gene expression levels of IL-1, IL-6 and TNF-α in liver tissues were assessed via RT-qPCR using SYBR Green (cat. no. G3320; Wuhan Servicebio Technology Co., Ltd.). The PCR conditions were as follows: Initial denaturation at 95˚C for 15 min, denaturation at 95˚C for 10 sec, followed by annealing at 58˚C for 30 sec and extension at 72˚C for 30 sec for 40 cycles. Relative gene expression profiles were determined by normalization of expression to that of the housekeeping gene (β-actin) using the 2^△△Cq method (51). Mouse primer sequences were as follows: IL-1β forward, 5'-GGTCAAGG TTTGGAAGCAG-3' and reverse, 5'-TGTGAAATGGCCACTT TTTGA-3'; IL-6 forward, 5'-ACCAGAGGAATTTCACA TAGGC-3' and reverse, 5'-TGTAGCACCCTGCGAAGAAA CA-3'; TNF-α forward, 5'-AGGTTGCTGGCCCATAGAA CT-3' and reverse, 5'-CCACCAGCTCTCTGTCTC-3'; and β-actin forward, 5'-CTTACCTCTGGAGAAGA-3' and 5'-reverse GGAAGGAGGCGTGGAA-3'.

**Evaluation of expression levels of Bax, Bcl-2, caspase-3, cleaved-caspase-3, Keap1 and Nrf2.** In order to extract total protein, liver tissue was homogenized in RIPA lysis buffer (Wuhan Servicebio Technology Co., Ltd.) and then centrifuged 12,000 x g for 10 min at 4˚C to prepare a supernatant. The proteins were quantified using the bicinchoninic acid method. Equivalent amounts of protein (50 μg) were resolved via 12% SDS-PAGE and transferred onto PVDF membranes and blocked in 5% skimmed milk at room temperature for 1 h. Membranes were incubated with the following primary antibodies (all 1:1,000) at 4˚C for 12 h: Anti-Bax (cat. no. GB11690; Wuhan Servicebio Technology Co., Ltd.), anti-Bcl-2 (cat. no. PAA778Mu01; Wuhan Servicebio Technology Co., Ltd.), anti-caspase-3 (cat. no. 66470-2-lg; ProteinTech Group, Inc.), anti-cleaved-caspase-3 (cat. no. 9664; Cell Signaling Technology, Inc.), anti-Keap1 (cat. no. 10503-2-ap; ProteinTech Group, Inc.), anti-Nrf2 (cat. no. 16396-1-ap; ProteinTech Group, Inc.) and anti-β-actin (cat. no. 66470-2-lg; Wuhan Servicebio Technology Co., Ltd.). Next, the membranes were washed three times with TBS-0.1% Tween-20, followed by incubation at room temperature for 1 h with horseradish peroxidase-conjugated secondary antibody (1:3,000; cat. no. GB23303; Wuhan Servicebio Technology Co., Ltd.), and washing three times. The proteins were visualized using an ECL Detection reagent (TransGen Biotech Co., Ltd.) and imaged using a Tanon-1600 Gel Image Analysis system (Tanon Science and Technology Co., Ltd.). Densitometry was performed using Tanon Gis 1D software (4.00; Tanon Science and Technology Co., Ltd.). Densitometry was performed using Tanon Gis 1D software (4.00; Tanon Science and Technology Co., Ltd.). All data are presented as the mean ± SEM. Each experiment was repeated more than three times. Comparisons were analyzed via one-way ANOVA followed by post hoc Tukey's test. P<0.05 was considered to indicate a statistically significant difference.

**Results**

**Effect of MgIG on ALT and AST levels.** ATO group exhibited markedly higher liver weight and index and ALT and AST activity compared with the CON and MgIG groups (P<0.01; Fig. 2A; Table I). MgIG treatment decreased the liver index and activity of ALT and AST compared with the ATO group (P<0.05 or P<0.01).

**Effect of MgIG on liver histopathology.** Histopathological data are shown in Fig. 2B and C. Liver tissue of mice in the CON and MgIG groups exhibited a normal structure. Severe pathological changes were observed in liver sections in the ATO group, including extensive hepatocyte vacuolation, disorganization of the parenchyma and dilatation of intrahepatocyte spaces. Furthermore, masses of acidophilic material were observed next to the central vein and microvesicular vacuolization was observed near the portal triad. Comparison of the histological features in mice from the ATO, H-MgIG and L-MgIG groups showed that pretreatment with MgIG diminished infiltration of inflammatory cells and vacuolation of hepatocytes.

**Effect of MgIG on ROS production.** The effect of MgIG on ATO-induced liver injury was evaluated via fluorescence of a dihydroethidium probe to assessing liver tissue production of ROS. ATO group exhibited significantly increased production of ROS compared with CON (P<0.01; Fig. 3A and B). However, the levels of ROS in H-MgIG and L-MgIG groups decreased significantly compared with ATO group (P<0.05 or P<0.01). These data indicated that MgIG suppressed ATO-induced hepatic ROS overproduction.

**Effects of MgIG on activity of antioxidant enzymes.** ATO caused a prominent decrease in CAT, GSH and SOD activity compared with the CON and MgIG groups. Treatment with H-MgIG and L-MgIG (25 or 50 mg/kg) elevated the activity of GSH, SOD and CAT in serum compared with the ATO group (P<0.01; Fig. 3C-F). Additionally, treatment with ATO increased MDA concentration, whereas MgIG significantly reversed this effect (P<0.05 or P<0.01).

**TUNEL assay.** TUNEL staining was performed using an in-situ cell death detection kit (cat. no. WLA029; Wanleibio Co., Ltd.) according to the manufacturer's protocol. After the liver was removed, tissues were fixed in 4% paraformaldehyde for 24 h at room temperature, embedded in paraffin and cut into 5-μm thick sections. Liver sections were deparaffinized, dehydrated using increasing concentrations of alcohol, washed in distilled water followed by PBS and deproteinized using proteinase K (20 μg/ml) at 37˚C for 30 min. Subsequently, sections were rinsed and incubated with the TUNEL reagent at 37˚C for 1 h. Following rinsing, the sections were visualized using peroxidase-conjugated anti-fluorescein antibody (contained in the TUNEL kit) with 0.02% 3,3-diaminobenzidine at room temperature for 5 min and then counterstained with 0.5% hematoxylin (cat. no. H8070; Beijing Solarbio Science & Technology Co., Ltd.) at room temperature for 10-30 sec. Neutral balsam was used to bond the slides and cover glass together. A total of five randomly selected microscopic fields of view were selected in order to analyze the staining results, and micrographs were scanned at x400 magnification with a digital light microscope system (Olympus Corporation; DP73).

**Statistical analysis.** Statistical analysis was performed using Origin Pro version 9.1 software (OriginLab Corporation.). Data are presented as the mean ± SEM. Each experiment was repeated more than three times. Comparisons were analyzed via one-way ANOVA followed by post hoc Tukey's test. P<0.05 was considered to indicate a statistically significant difference.
Effect of MgIG on IL-1β, IL-6 and TNF-α expression levels. In order to assess the protective effect of MgIG, the levels of IL-1β, IL-6, and TNF-α were measured. Levels of IL-1β, IL-6, and TNF-α in the ATO group were significantly higher than those in the CON group (P<0.01; Fig. 4A). Treatment with MgIG (25 or 50 mg/kg) inhibited IL-1β, IL-6 and TNF-α expression (P<0.01). These results revealed that MgIG attenuated IL-1β, IL-6 and TNF-α expression levels.

mRNA expression levels of proinflammatory cytokines, such as IL-6, IL-1β and TNF-α, significantly increased in the liver of ATO mice compared with the CON group (P<0.01; Fig. 4B). Compared with the ATO group, the levels of IL-6, IL-1β and TNF-α in H-MgIG and L-MgIG groups was significantly decreased (P<0.01).

Effect of MgIG on Bax, Bcl-2, caspase-3 and cleaved-caspase-3 expression levels. Western blotting was performed on liver tissue to detect the expression levels of Bax, Bcl-2, caspase-3 and cleaved-caspase-3 to assess the effect of MgIG against ATO-induced hepatotoxicity. Apoptosis induced by ATO was significantly increased compared with the CON group (P<0.01; Fig. 5). Compared with the CON group, caspase-3, cleaved-caspase-3 and Bax expression levels were increased and Bcl-2 expression was significantly decreased in the ATO group.

Table I. Effect of MgIG on body weight and relative liver weight in mice.

| Parameter               | CON         | ATO         | MgIG        | H-MgIG      | L-MgIG      |
|-------------------------|-------------|-------------|-------------|-------------|-------------|
| Final body weight, g    | 30.78±0.72  | 29.71±0.91  | 30.05±0.63  | 29.13±1.05  | 29.02±0.78  |
| Liver weight, g         | 1.31±0.05   | 3.43±0.09a  | 1.19±0.04b  | 1.78±0.08b  | 2.36±0.03b  |
| Liver index, %          | 4.27±0.20   | 11.54±0.43a | 3.94±0.10b  | 6.13±0.35b  | 8.18±0.30b  |

Data are presented as the mean ± SEM (n=10). *P<0.01 vs. CON, †P<0.01 vs. ATO. MgIG, magnesium isoglycyrrhizinate; ATO, arsenic trioxide; CON, control; H-, high; L-, low.

Figure 2. Effect of MgIG on liver injury. (A) AST and ALT activity. Representative sections of hematoxylin-eosin staining in the hepatic (B) central vein and (C) duct area (magnification, x400). Scale bar, 50 µm. CON showed normal hepatocyte architecture; ATO showed inflammation, hepatocyte vacuolation and necrosis/disorganization of the parenchyma. These symptoms decreased following MgIG treatment. Data are presented as the mean ± SEM (n=10). **P<0.01 vs. CON, #P<0.05 and ##P<0.01 vs. ATO. AST, aspartate aminotransferase; ALT, alanine aminotransferase; MgIG, magnesium isoglycyrrhizinate; CON, control; ATO, arsenic trioxide; H-, high; L-, low.
group (P<0.01). Compared with the ATO group, treatment with MgIG (25 or 50 mg/kg) inhibited Bax, caspase-3 and cleaved-caspase-3 expression and increased Bcl-2 expression (P<0.05 or P<0.01). These results revealed that MgIG could reduce apoptosis in ATO-induced liver injury.

**Effect of MgIG on TUNEL staining.** Apoptosis in hepatic cells remained at consistently low levels in the CON group (Fig. 6). However, TUNEL-positive hepatic cells showed a significant increase in the ATO group (P<0.01). Both H-MgIG and L-MgIG inhibited this effect (P<0.01).

**Effect of MgIG on Keap1-Nrf2 expression.** The protein expression of Keap1 in ATO-induced mice significantly increased compared with the CON group (P<0.01; Fig. 7A and C). Treatment with MgIG (25 or 50 mg/kg) significantly decreased expression levels of Keap1 in the liver of ATO-induced mice (P<0.05). ATO decreased Nrf2 expression compared with the CON group (P<0.01; Fig. 7B and D), but there were no significant changes in the MgIG-alone group compared with the CON group. Nrf2 expression was increased following treatment with 25 or 50 mg/kg MgIG, which suggested that Nrf2 expression was upregulated (P<0.05 or P<0.01).
Discussion

Current cancer treatment methods include chemotherapy, surgery and radiotherapy. Traditional Chinese medicine and its components also show strong anti-tumor effects (52). ATO is a primary component in traditional Chinese medicine that is effective in the treatment of both newly diagnosed and relapsed patients with APL (53). However, it can also lead to liver toxicity, which limits its clinical application in cancer treatment (54,55). Thus, it is important to find a suitable ATO antidote.

Licorice is an herbal medicine and natural sweetener that is widely used in China and contains numerous active ingredients; its extracts exhibit anti-viral, anti-bacterial, anti-inflammatory, anti-cancer and anti-oxidant activity (56). MgIG is a 4th-generation glycyrrhizic acid agent extracted from licorice by alkali isomerization catalysis; it is currently used as a liver-protecting agent in clinical treatment (57). The therapeutic effects of MgIG in the treatment of liver disease has been confirmed in liver disease models, including drug-induced and immune-mediated liver injury and fatty liver disease (58). The aim of the present study was to investigate the protective effect and potential mechanism of MgIG on liver injury induced by ATO.

Hepatotoxicity is caused by increased inflammatory cytokines, oxidative stress and apoptosis. This is a major drawback of adverse reactions of various anti-cancer and anti-tubercular drugs (59). Here, the activity of hepatic marker enzymes in serum significantly increased following treatment with ATO, which may be due to leakage of enzymes into the blood stream (60). MgIG significantly reverses increased ALT and AST activity in serum, indicating that MgIG restores ATO-induced liver injury (61). These results are associated with hepatotoxicity induced by ATO, which was confirmed here by histopathological examination. The histological sections of the liver were normal in the CON and MgIG groups, but ATO caused serious liver disease, including cellular necrosis, inflammatory cell infiltration, pyknotic nuclei and vacuolated hepatocytes. Slight hepatocyte swelling and bleeding were observed in the H-MgIG and L-MgIG groups, suggesting that pretreatment with MgIG diminished liver injury.

Oxidative stress is a result of the imbalance between ROS and antioxidants in the body and leads to oxidative damage of macromolecules; this has been implicated in the pathogenesis of numerous types of disease, including chronic kidney disease, atherosclerosis and Alzheimer's disease (62-65). The production of mitochondrial ROS is increased upon exposure to xenobiotics, especially ATO, which can overwhelm the antioxidant defense mechanism and damage cellular ingredients such as DNA, proteins and lipids (66,67). Mitochondria are the central site for ROS generation and energy metabolism (68). Thus, uncontrolled overproduction of ROS can overwhelm the cellular antioxidant capacity and impair the mitochondria (69). Antioxidants inhibit oxidative stress via inhibiting production of ROS and improve the function of mitochondria (70). Therefore, antioxidants are a good therapeutic strategy for treatment of liver disorders in light of the key role of oxidative stress in liver disease (71).

The present study showed that exposure to ATO significantly increased ROS generation in hepatocytes compared
with the CON group. The level of ROS in the ATO was notably attenuated by MgIG at both high and low doses. Antioxidant enzymes, such as SOD, CAT and GSH, are second line cellular defenses against oxidative liver injury (72-74). Changes in levels of these enzymes is an indirect method to evaluate the antioxidant-prooxidant condition in ATO (75). Their inactivation leads to further oxidative damage. In the present study, MDA content increased gradually upon aggravation of liver damage. In recent years, the powerful antioxidant and free radical scavenging activity of MgIG have been extensively reported in in vitro experiments (76,77). Here, the antioxidant effect of MgIG was demonstrated using an animal model. There were notably increased levels of SOD, GSH and CAT following treatment with MgIG, along with decreased
MDA content, which demonstrated that MgIG alleviated ATO-induced oxidative damage. These data suggested that MgIG suppressed ATO-induced hepatic ROS overproduction.

Activation of the antioxidant system requires inhibition of the inflammatory response and cell apoptosis (78). Inflammatory factors are activated in response to toxic damage via ATO-induced hepatotoxicity (79). One of the marks of the inflammatory response is the production of pro-inflammatory mediators, which are needed to repair injured tissue. IL-1β, IL-6 and TNF-α are key pro-inflammatory factors of the immune response; they primarily serve pro-inflammatory roles that aggravate further tissue damage (80). Pro-inflammatory cytokines, such as IL-1β, IL-6 and TNF-α, exhibited enhanced expression in the liver, which confirmed ATO-induced
hepatotoxicity. MgIG inhibited the expression levels of inflammatory cytokines. Oxidative stress is positively associated with cell apoptosis (81).

Apoptosis is programmed cell death that leads to death or morphological changes in the cell to replace older cells with newer cells. Apoptosis involves a series of active death processes and is regulated by multiple genes associated with the pro-apoptotic Bax subfamily and the anti-apoptotic Bcl-2 subfamily (82,83). Caspase-3 is the ‘effector’ protease in the apoptosis cascade and is one of the primary executors of apoptosis (84). One of the best-known markers of apoptosis is proteolytic cleavage of pro-caspase-3 into its active form, caspase-3 (85). When cells undergo apoptosis, caspase-3 is activated to cleaved caspase-3, which promotes apoptosis (86). Here, ATO caused excessive ROS production and promoted apoptosis. ATO is cytotoxic and causes liver injury; it also decreases cell activity and increases apoptosis (35,87). The increase in expression levels of Bax in the ATO group, concomitant with a decrease in the expression levels of Bcl-2, demonstrated apoptotic events in ATO mice; however, there were significant improvements following treatment with MgIG. Compared with the ATO-induced hepatotoxicity group, MgIG notably decreased the expression levels of caspase-3 and cleaved caspase-3 and the number of TUNEL-positive cells in the liver tissue. These biological indices suggested that MgIG treatment ameliorated liver injury induced by ATO.

The exact mechanism of ATO-induced hepatotoxicity remains unclear, but it has been reported that reactive metabolites decrease Nrf2 levels, induce ROS production and inhibit an endogenous antioxidant defense system that results in severe oxidative stress (88,89). Nrf2 is a key antioxidant transcription factor that is recognized as a primary transcriptional regulation pathway involved in the metabolism and detoxification of toxic substances (90,91). The mechanism by which ATO inhibits Nrf2 expression may involve accelerating Nrf2 degradation by promoting Keap1 protein expression levels (92). Zhao et al (41) demonstrated that activating Nrf2 and expression levels of Nrf2-regulated antioxidant enzymes and detoxification protects HaCaT cells from ATO-induced cytotoxicity and apoptosis. In the present study, the decrease in Nrf2 content induced by ATO indicates that excessive oxidative stress consumes a large amount of Nrf2 or disrupts homeostasis between Nrf2 production and degradation. This damages the antioxidant defense system and constantly aggravates injury unless alleviated. However, MgIG maintained high levels of Nrf2 in the liver and protected the antioxidative defense system to attenuate oxidative stress and prevent ATO-induced liver injury.

Here, MgIG restrained ATO-mediated hepatotoxicity by inhibiting oxidative stress, inflammation and apoptosis (Fig 8). The potential molecular mechanism of MgIG’ hepatoprotection may be due to activation of the Keap1-Nrf2 signaling pathway. Overall, MgIG exhibited a protective potential effect on ATO-induced hepatotoxicity. Future experiments are needed to delineate the specific mechanism involved in this protective function.
Acknowledgements

Not applicable.

Funding

The present study was supported by the Research Foundation of Administration of Traditional Chinese Medicine of Hebei Province, China (grant no. 2020188), Research Foundation of Hebei University of Chinese Medicine (grant no. KTZ2019041) and the open projects of Hebei Key Laboratory of Integrative Medicine on Liver-kidney Patterns (grant no. B 201907).

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Authors' contributions

XH, LC and JS contributed to the design of the experiments. ML, BZ, YaL, JZ and CD performed experiments and obtained the data. YiL, XC and PL analyzed the data. ML and PL wrote the manuscript. MLC and JZ revised the manuscript. ML and XH confirm the authenticity of all the raw data. All authors read and approved the final manuscript.

Ethics approval and consent to participate

All operating procedures regarding experimental animals were approved by the Ethics Committee for Animal Experiments of Hebei University of Chinese Medicine (approval no. DWLL2020005).

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References

1. Centeno JA, Mulligk FG, Martinez L, Page NP, Gibb H, Longfellow D, Thompson C and Ladich ER: Pathology related to chronic arsenic exposure. Environ Health Perspect 110 (Suppl 5): S883-S886, 2002.
2. Emadi A and Gore SD: Arsenic trioxide-An old drug rediscovered. Blood Rev 24: 191-199, 2010.
3. Gore SD, Gojo J, Sekeres MA, Morris L, Devetten M, Jamieson K, Redner RL, Arceci R, Owwey I, Dauses T, et al: Single cycle of arsenic trioxide-based consolidation chemotherapy spares anthraccline exposure in the primary management of acute promyelocytic leukemia. J Clin Oncol 28: 1047-1053, 2010.
4. Antman KH: Introduction: The history of arsenic trioxide in cancer therapy. Oncologist 6 (Suppl 2): S1-S2, 2001.
5. Abaza Y, Kantarjian H, Garcia-Manero G, Estey E, Borthakur G, Jabbour E, Faderl S, O'Brien S, Wierda W, Pierce S, et al: Long-term outcome of acute promyelocytic leukemia treated with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab. Blood 129: 1275-1283, 2017.
6. Breccia M and Lo-Coco F: Arsenic trioxide for management of acute promyelocytic leukemia: Current evidence on its role in front-line therapy and recurrent disease. Expert Opin Pharmacother 13: 1031-1043, 2012.
7. Hland HJ, Bradstock K, Supple SG, Catalano A, Collins M, Hertzberg M, Browett P, Grigg A, Firkin F, Hugman A, et al: All-trans-retinoic acid, idarubicin, and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia (APML4). Blood 172: 1570-1580, 2011.
8. Lo-Coco F, Avvisati G, Vignetti M, Thiede C, Orlando SM, Iacobelli S, Ferrara F, Fazi P, Cicconi L, Di Bona E, et al: Retinoic acid and arsenic trioxide for acute promyelocytic leukaemia. N Engl J Med 369: 111-121, 2013.
9. Zhang X, Jia S, Yang S, Yang Y, Yang T and Yang Y: Arsenic trioxide induces G2/M arrest in hepatocellular carcinoma cells by increasing the tumor suppressor PTEN expression. J Cell Biochem 113: 3528-3535, 2012.
10. Walker AM, Stevens JJ, Ndebele K and Tchounwou PB: Evaluation of arsenic trioxide potential for lung cancer treatment: Assessment of apoptotic mechanisms and oxidative damage. J Cancer Ther 8: 1-9, 2016.
11. Messarah M, Klibet F, Boumendjal A, Abdennour C, Bouzerna N, Boulakoud MS and El Feki A: Hepatoprotective role and antioxident capacity of selenium on arsenic-induced liver injury in rats. Exp Toxicol Pathol 64: 167-174, 2012.
12. Miller WH Jr, Schipper HM, Lee JS, Singer J and Waxman S: Mechanisms of action of arsenic trioxide. Cancer Res 62: 3893-3903, 2002.
13. Jin W, Xue Y, Xue Y, Han X, Song Q, Zhang J, Li Z, Cheng J, Guan S, Sun S and Chu L: Tannic acid ameliorates arsenic trioxide-induced nephrotoxicity, contributions of NF-κB and Nrf2 pathways. Biomed Pharmacother 126: 110047, 2020.
14. Liu Y, Liang Y, Zheng B, Chu L, Ma D, Wang H, Chu X and Zhang J: Protective effects of crocetin on arsenic trioxide-induced hepatic injury: Involvement of suppression in oxidative stress and inflammation through activation of Nrf2 signaling pathway in rats. Drug Des Dev Ther 14: 1921-1931, 2020.
15. Li M, Liu P, Xue Y, Liang Y, Shi J, Han X, Zhang J, Chu X and Chu L: Tannic acid attenuates hepatic oxidative stress, apoptosis and inflammation by activating the Keap1/Nrf2/ARE signaling pathway in arsenic trioxide-toxicated rats. Oncol Rep 44: 2306-2316, 2020.
16. Benramdane L, Accominti M, Fanton L, Malicier D and Vallon JJ: Arsenic speciation in human organs following fatal arsenic trioxide-poisoning-a case report. Clin Chem 45: 301-306, 1999.
17. Xu M, Rui D, Yan Y, Xu S, Niu Q, Feng G, Wang Y, Li S and Jing M: Oxidative damage induced by arsenic in mice or rats: A systematic review and meta-analysis. Biol Trace Elem Res 176: 154-157, 2020.
18. Valko M, Morris H and Cronin MT: Metals, toxicity and oxidative stress. Curr Med Chem 12: 1161-1208, 2005.
19. Alam MF, Khan G, Safhi MM, Alshahrani S, Siddiqui R, Sivagurunathan Moni S and Anwer T: Thymoquinone ameliorates doxorubicin-induced cardiotoxicity in swiss albino mice by modulating oxidative damage and cellular inflammation. Cardiol Res Pract 2018: 1483041, 2018.
20. Kim SY, Park C, Jang HJ, Kim BO, Bae HW, Chung IY, Kim ES and Cho YH: Antibacterial strategies inspired by the oxidative stress and response networks. J Microbiol 57: 203-212, 2019.
21. Sies H and Jones DP: Reactive oxygen species (ROS) as pleiotropic physiological signalling agents. Nat Rev Mol Cell Biol 21: 363-383, 2020.
22. Mortezaee K and Khanlarkhani N: Melatonin application in targeting oxidative-induced liver injuries: A review. J Cell Physiol 233: 4015-4032, 2018.
23. Grossini E, Bellofatto K, Farruggio S, Sigaudo L, Marotta P, Raina G, De Giuli V, Mary D, Pollesello P, Minisini R, et al: Levosimendan inhibits peroxidation in hepatocytes by modulating apoptosis/autophagy interplay. PLoS One 10: e0124742, 2015.
24. Weiskirchen R and Tacke F: Relevance of autophagy in parenchymal and non-parenchymal liver cells for health and disease. Cells 8: 16, 2019.
25. Barrera C, Valenzuela R, Rincon MA, Espinosa A, Echeverria F, Romero N, Gonzalez-Mañan D and Videla LA: Molecular mechanisms related to the hepatoprotective effects of antioxidant-rich extra virgin olive oil supplementation in rats subjected to short-term iron administration. Free Radic Biol Med 126: 313-321, 2018.
44. Ma D, Zhang J, Zhang Y, Zhang X, Han X, Song T, Zhang Y and Chu L: Inhibition of myocardial hypertrophy by magnesium isoglycyrrhizinate through the TLR4/NF-κB signaling pathway. Int Immunopharmacol 55: 237-244, 2018.

45. Xue Y, Li M, Xue Y, Jin W, Han X, Zhang J, Chu X, Li Z and Chu L: Mechanisms underlying the protective effect of tannic acid against arsenic trioxide-induced cardiotoxicity in rats: Potential involvement of mitochondrial apoptosis. Mol Med Rep 22: 4663-4674, 2015.

46. Liu W, Chen Q, Li P, Lu Q, Pei X, Sun Y, Yang W and Hao K: Magnesium Isoglycyrrhizinate attenuates lipopolysaccharide-induced depressive-like behavior in mice. Biomed Pharmacother 86: 177-184, 2017.

47. Birari LA, Mahajan UB, Patil KR, Patil DD, Bagul NA, Bilemikar S, Goyal SN, Ojha S and Patil CR: Aloxin protects against arsenic trioxide-induced myocardial membrane damage and release of inflammatory cytokines. Naunyn Schmiedebergs Arch Pharmacol 393: 1365-1372, 2020.

48. Dugo EB, Yedjou CG, Stevens JJ and Thionouw PB: Therapeutic potential of arsenic trioxide (ATO) in treatment of hepatocellular carcinoma via modulation of oxidative stress in ATO-induced apoptosis. Ann Clin Pathol 169: 121-128, 2016.

49. Sharanek A, Burban A, Ciarciam N and Gligouloz A: Pro-inflammatory cytokines enhance dilatation of bile canaliculi caused by cholestatic toxins. Toxicol In Vitro 58: 51-59, 2019.

50. Tu C, Gao D, Li XF, Li CY, Li RS, Zhao YL, Li N, Jia GL, Pang JY, Cui HR, et al: Inflammatory stress potentiates emodin-induced liver injury in rats. Front Pharmacol 6: 233, 2015.

51. Zhang J, Li C, Li Y, Wang F and Zhang Z: Double-sided personality: Effects of arsenic trioxide on inflammation. Inflammation 41: 1128-1134, 2018.

52. Dugo EB, Yedjou CG, Stevens JJ and Thionouw PB: Therapeutic potential of arsenic trioxide (ATO) in treatment of hepatocellular carcinoma via modulation of oxidative stress in ATO-induced apoptosis. Ann Clin Pathol 169: 121-128, 2016.

53. Adams JM and Cory S: The Bcl-2 apoptotic switch in cancer development and therapy. Oncogene 26: 1324-1337, 2007.

54. Cheung C, Esfandiarei M, Rudin CM, Thompson CB, Adams JM and Cory S: The Bcl-2 apoptotic switch in cancer development and therapy. Oncogene 26: 1324-1337, 2007.

55. Mathews V, Desire S, George B, Lakshmi KM, Rao JG, Viswabandaya A, Bajel A, Srivastava VM, Srivastava A and Chandy M: Hepatoprotective profile of single agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia, its impact on clinical outcome and the effect of genetic polymorphisms on the incidence of hepatotoxicity. Leukemia 20: 881-883, 2006.

56. Ducas RA, Seftel MD, Ducas J and Seifer C: Monomorphic ventricular tachycardia caused by arsenic trioxide therapy for acute promyelocytic leukaemia. J R Coll Physicians Edinb 41: 117-118, 2011.

57. Wang ZF, Liu J, Yang YG and Zhu HL: A review: The anti-inflammatory, anticancer and antibacterial properties of four kinds of licorice flavonoids isolated from licorice. Curr Med Chem 27: 1673-1682, 2020.

58. Ducas J, Chen WY, Chen X, Jia YM, Peng GQ and Chen L: Enhanced elimination of the Nrf2-activated antioxidant capacity. Redox Biol 21: 100168, 2019.

59. MitoNurpau S, Sumedha NC and Senthilraja P: Diallyl trisulfide, an allyl disulphide protects against As-induced renal oxidative nephropathy, apoptosis and inflammation in rats by activating the Nrf2/ARE signaling pathway. Int Immunopharmacol 165: 104195, 2021.

60. Cetin A, Kaycigil I, Hochguggl SK, Saraymen R, Ozturk A, Sari I and Sagdic O: Role of grape seed extract on methotrexate induced oxidative stress in rat liver. Am J Chin Med 42: 1177-1188, 2014.

61. Kim WR, Flamm SL, Di Bisceglie AM, Bodenheimer HC and Public Policy Committee of the American association for the study of liver disease: Serum activity of alanine aminotransferase (ALT) as an indicator of health and disease. Hepatology 47: 1367-1370, 2008.

62. Yang RZ, Park S, Reagan WJ, Goldstein R, Zhong S, Lawton M, Rajamohan F, Qian K, Liu L and Gong DW: Alanine aminotransferase isoforms: Molecular cloning and quantitative analysis of tissue expression in rats and serum elevation in liver toxicity. Hepatology 49: 598-607, 2009.

63. Sifuentes-Franco S, Pacheco-Moises FP, Rodriguez-Carrizalez AD and Miranda-Diaz AG: The role of oxidative stress, mitochondrial function, and autophagy in diabetic polyneuropathy. J Diabetes Res 2017: 1673081, 2017.

64. Bann MR, Andreis A, Mekahdi D, Van Schepdael A, Jourret F and Bammens B: Oxidative stress in chronic kidney disease. Pediatr Nephrol 34: 975-991, 2019.
Cleaved caspase-3 transcriptionally regulates κ-B-induced inflammation. Toxicol Appl Pharm 265: 292-299, 2012.

Lantz RC and Zhang DD: Sulforaphane prevents pulmonary damage in response to inhaled arsenic by activating the Nrf2-defense response. Toxicol Appl Pharm 265: 292-299, 2012.

Zheng Y, Tao S, Lian F, Chau BT, Chen J, Sun G, Fang D, Lantz RC and Zhang DD: Sulforaphane prevents pulmonary damage in response to inhaled arsenic by activating the Nrf2-defense response. Toxicol Appl Pharm 265: 292-299, 2012.